author-photo

Gloria Borra

11

Papers

231

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

P84.05 Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients

2020
Show All
- Source
- Cite
- Save
Citations (1)
Be-TeaM: an Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients

2020 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (4)
Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial

2019 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (66)
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (34)
Emerging targets in advanced non-small-cell lung cancer

2018 Future Oncology
Show All
- Source
- Cite
- Save
Citations (12)
Listening understanding and acting (lung): focus on communicational issue in thoracic oncology

2018 Translational cancer research
Show All
- Source
- Cite
- Save
Citations (0)
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (104)